JAMES J. BOCHNOWSKI - 17 May 2023 Form 4 Insider Report for Jaguar Health, Inc. (JAGX)

Role
Director
Signature
/s/ Lisa A. Conte, Attorney-in-Fact
Issuer symbol
JAGX
Transactions as of
17 May 2023
Transactions value $
$0
Form type
4
Filing time
19 May 2023, 17:04:47 UTC
Previous filing
18 May 2022
Next filing
14 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JAGX Common Stock Options Exercise +1.28K +130.21% 2.26K 17 May 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JAGX Restricted stock units Options Exercise $0 -1.28K -100% $0.00* 0 17 May 2023 Common Stock 1.28K Direct F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Granted pursuant to the issuer's 2014 Stock Incentive Plan.
F2 Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F3 On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock.
F4 The restricted stock units were previously reported as covering 96,015 shares, but were adjusted to reflect the January 2023 Reverse Stock Split. Such restricted stock units were granted on March 28, 2022 and vested in full on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice.